Ag85A, As an S2 Vaccine Carrier, Reduces the Toxicity of the S2 Vaccine and Enhances the Protective Ability of Mice against Brucella

Brucella is a globally distributed zoonotic disease that can cause abortion and changes in immune function in humans and animals. At present, there is no good treatment plan for Brucella, and animals can only be treated harmlessly once they become ill, resulting in huge economic losses. Therefore, t...

Full description

Saved in:
Bibliographic Details
Main Authors: Shuai Zhang, Lumen Chao, Lemuge She, Humujile Sui, Huaxin Niu, Zeliang Chen, Xiangyang Li, Jingbo Zhai
Format: Article
Language:English
Published: Wiley 2022-01-01
Series:Journal of Immunology Research
Online Access:http://dx.doi.org/10.1155/2022/4686541
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850211079126253568
author Shuai Zhang
Lumen Chao
Lemuge She
Humujile Sui
Huaxin Niu
Zeliang Chen
Xiangyang Li
Jingbo Zhai
author_facet Shuai Zhang
Lumen Chao
Lemuge She
Humujile Sui
Huaxin Niu
Zeliang Chen
Xiangyang Li
Jingbo Zhai
author_sort Shuai Zhang
collection DOAJ
description Brucella is a globally distributed zoonotic disease that can cause abortion and changes in immune function in humans and animals. At present, there is no good treatment plan for Brucella, and animals can only be treated harmlessly once they become ill, resulting in huge economic losses. Therefore, the prevention of Brucella infection is a very crucial step. Although a variety of Brucella vaccines have been widely used, they have varying degrees of shortcomings. For example, some Brucella vaccines have residual virulence, which leads to the emergence of Brucella in animals during the immunization process. Bacillus infection and other conditions occur. To further reduce the toxicity of the Brucella vaccine and enhance its protective effect on animals, this study used Antigen 85A (Ag85A) as a carrier of the Brucella vaccine to fuse with the Brucella S2 vaccine. The results of the study found that the S2-Ag85A oral Brucella vaccine could effectively reduce the toxicity residue of the S2 vaccine, stimulate the mice to produce a better immunogenic response, and effectively activate the expression levels of Brucella heterozygous IgG1 and IgG2a. Experiments have shown that the expression of IFN-γ in the peripheral blood serum and spleen of mice is significantly increased, and the expression levels of IL-1β, TNF-α, and IL-6 are significantly reduced, which may indicate that S2-Ag85A oral Brucella vaccine could induce the expression of IFN-γ, thus downregulating the expression levels of IL-6 and TNF-α in the spleen tissue. The above results indicate that the S2-Ag85A oral vaccine is an effective attenuated vaccine for preventing Brucella infection.
format Article
id doaj-art-8d8f6ac1a5f44b93a40cac85df98a7cb
institution OA Journals
issn 2314-7156
language English
publishDate 2022-01-01
publisher Wiley
record_format Article
series Journal of Immunology Research
spelling doaj-art-8d8f6ac1a5f44b93a40cac85df98a7cb2025-08-20T02:09:38ZengWileyJournal of Immunology Research2314-71562022-01-01202210.1155/2022/4686541Ag85A, As an S2 Vaccine Carrier, Reduces the Toxicity of the S2 Vaccine and Enhances the Protective Ability of Mice against BrucellaShuai Zhang0Lumen Chao1Lemuge She2Humujile Sui3Huaxin Niu4Zeliang Chen5Xiangyang Li6Jingbo Zhai7Medical CollegeCollege of Animal Science and TechnologyCollege of Animal Science and TechnologyCollege of Animal Science and TechnologyCollege of Animal Science and TechnologyMedical CollegeCollege of Animal Science and TechnologyMedical CollegeBrucella is a globally distributed zoonotic disease that can cause abortion and changes in immune function in humans and animals. At present, there is no good treatment plan for Brucella, and animals can only be treated harmlessly once they become ill, resulting in huge economic losses. Therefore, the prevention of Brucella infection is a very crucial step. Although a variety of Brucella vaccines have been widely used, they have varying degrees of shortcomings. For example, some Brucella vaccines have residual virulence, which leads to the emergence of Brucella in animals during the immunization process. Bacillus infection and other conditions occur. To further reduce the toxicity of the Brucella vaccine and enhance its protective effect on animals, this study used Antigen 85A (Ag85A) as a carrier of the Brucella vaccine to fuse with the Brucella S2 vaccine. The results of the study found that the S2-Ag85A oral Brucella vaccine could effectively reduce the toxicity residue of the S2 vaccine, stimulate the mice to produce a better immunogenic response, and effectively activate the expression levels of Brucella heterozygous IgG1 and IgG2a. Experiments have shown that the expression of IFN-γ in the peripheral blood serum and spleen of mice is significantly increased, and the expression levels of IL-1β, TNF-α, and IL-6 are significantly reduced, which may indicate that S2-Ag85A oral Brucella vaccine could induce the expression of IFN-γ, thus downregulating the expression levels of IL-6 and TNF-α in the spleen tissue. The above results indicate that the S2-Ag85A oral vaccine is an effective attenuated vaccine for preventing Brucella infection.http://dx.doi.org/10.1155/2022/4686541
spellingShingle Shuai Zhang
Lumen Chao
Lemuge She
Humujile Sui
Huaxin Niu
Zeliang Chen
Xiangyang Li
Jingbo Zhai
Ag85A, As an S2 Vaccine Carrier, Reduces the Toxicity of the S2 Vaccine and Enhances the Protective Ability of Mice against Brucella
Journal of Immunology Research
title Ag85A, As an S2 Vaccine Carrier, Reduces the Toxicity of the S2 Vaccine and Enhances the Protective Ability of Mice against Brucella
title_full Ag85A, As an S2 Vaccine Carrier, Reduces the Toxicity of the S2 Vaccine and Enhances the Protective Ability of Mice against Brucella
title_fullStr Ag85A, As an S2 Vaccine Carrier, Reduces the Toxicity of the S2 Vaccine and Enhances the Protective Ability of Mice against Brucella
title_full_unstemmed Ag85A, As an S2 Vaccine Carrier, Reduces the Toxicity of the S2 Vaccine and Enhances the Protective Ability of Mice against Brucella
title_short Ag85A, As an S2 Vaccine Carrier, Reduces the Toxicity of the S2 Vaccine and Enhances the Protective Ability of Mice against Brucella
title_sort ag85a as an s2 vaccine carrier reduces the toxicity of the s2 vaccine and enhances the protective ability of mice against brucella
url http://dx.doi.org/10.1155/2022/4686541
work_keys_str_mv AT shuaizhang ag85aasans2vaccinecarrierreducesthetoxicityofthes2vaccineandenhancestheprotectiveabilityofmiceagainstbrucella
AT lumenchao ag85aasans2vaccinecarrierreducesthetoxicityofthes2vaccineandenhancestheprotectiveabilityofmiceagainstbrucella
AT lemugeshe ag85aasans2vaccinecarrierreducesthetoxicityofthes2vaccineandenhancestheprotectiveabilityofmiceagainstbrucella
AT humujilesui ag85aasans2vaccinecarrierreducesthetoxicityofthes2vaccineandenhancestheprotectiveabilityofmiceagainstbrucella
AT huaxinniu ag85aasans2vaccinecarrierreducesthetoxicityofthes2vaccineandenhancestheprotectiveabilityofmiceagainstbrucella
AT zeliangchen ag85aasans2vaccinecarrierreducesthetoxicityofthes2vaccineandenhancestheprotectiveabilityofmiceagainstbrucella
AT xiangyangli ag85aasans2vaccinecarrierreducesthetoxicityofthes2vaccineandenhancestheprotectiveabilityofmiceagainstbrucella
AT jingbozhai ag85aasans2vaccinecarrierreducesthetoxicityofthes2vaccineandenhancestheprotectiveabilityofmiceagainstbrucella